Media stories about Motif Bio (NASDAQ:MTFB) have trended somewhat positive recently, according to Accern. The research firm ranks the sentiment of press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Motif Bio earned a media sentiment score of 0.20 on Accern’s scale. Accern also gave headlines about the company an impact score of 44.1811666544706 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

Several analysts have recently commented on the stock. WBB Securities initiated coverage on shares of Motif Bio in a research note on Friday, December 29th. They set a “sell” rating and a $7.00 price target on the stock. Seaport Global Securities restated a “buy” rating on shares of Motif Bio in a report on Friday, December 22nd. Finally, ValuEngine upgraded shares of Motif Bio from a “strong sell” rating to a “sell” rating in a report on Friday, February 2nd. Two research analysts have rated the stock with a sell rating and three have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $21.33.

Motif Bio (NASDAQ:MTFB) opened at $10.30 on Tuesday. Motif Bio has a twelve month low of $5.80 and a twelve month high of $13.75.

COPYRIGHT VIOLATION WARNING: “Somewhat Positive Media Coverage Somewhat Unlikely to Affect Motif Bio (MTFB) Stock Price” was first reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this article on another domain, it was stolen and reposted in violation of international copyright & trademark law. The legal version of this article can be accessed at

About Motif Bio

Motif Bio plc, a clinical stage biopharmaceutical company, develops and commercializes pharmaceutical formulations in the United States. The company develops novel antibiotics for the treatment of serious and life-threatening infections caused by multi-drug resistant bacteria. Its lead product candidate is Iclaprim, a novel antibiotic that is in Phase III clinical trials to treat bacterial infections, such as acute bacterial skin and skin structure infections, and hospital acquired bacterial pneumonia caused by methicillin-resistant staphylococcus aureus.

Insider Buying and Selling by Quarter for Motif Bio (NASDAQ:MTFB)

Receive News & Ratings for Motif Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Motif Bio and related companies with's FREE daily email newsletter.